Divergent M&A Cultures, Convergent Goals: Johnson & Johnson and Boston Scientific's Strategic Paths in MedTech

Johnson & Johnson and Boston Scientific are the most active medical device companies in the mergers and acquisitions market in recent years. Both companies advocate enhancing their competitiveness in different medical device fields through acquisitions. However, these two companies have different approaches in executing their giant merger tactics.

Johnson & Johnson is like the powerful "Kung Fu" in Jin Yong's martial arts dramas --- the Eighteen Dragon-Subduing Palms --- bold and sweeping, rapidly enhancing its strength through large-scale mergers and acquisitions.Johnson & Johnson's pursuit is high risk, high-return markets, as these markets have a large number of unmet clinical needs.

However, Boston Scientific's acquisition strategy is completely different from that of Johnson & Johnson, resembling the "Beiming Divine Skill" in continuously absorbing small amounts of internal strength, eventually converging into a powerful force. Boston Scientific continuously...Small-scale acquisitions to strengthen existing product lines (with high growth potential in complementary products), thereby creating synergy (1+1>2) and providing continuous growth momentum for the business.

Johnson & Johnson and Boston Scientific differ not only in the scale of their acquisitions but also in their areas of focus. Johnson & Johnson concentrates on the cardiovascular field, while Boston Scientific, in addition to cardiovascular, also covers its traditional areas of strength such as urology, pain management, and gastroenterology.

There are many cultural reasons for the large-scale mergers and acquisitions by Johnson & Johnson and Boston Scientific.One of the reasons is that the scale of Johnson & Johnson and Boston Scientific differs significantly. Johnson & Johnson's sales in 2023 were $85.159 billion, while Boston Scientific's sales in 2023 were $14.24 billion—Johnson & Johnson's revenue was nearly six times that of Boston Scientific.

The second reason is that Boston Scientific has had a precedent.InIn 2006, Boston Scientific acquired Guidant for $27 billion (a deal indirectly facilitated by Johnson & Johnson), marking the second-largest merger and acquisition in the history of the medical device industry. This acquisition nearly bankrupted Boston Scientific, and since then, the company has avoided acquisitions exceeding $10 billion, as they proved indigestible.

Although Johnson & Johnson has also experienced failed mergers and acquisitions, its large size ensures that even failures do not significantly impact the company.

The third reason is that Boston Scientific and Johnson & Johnson have different philosophies. Johnson & Johnson hopes to achieveGame-changing targets in high-growth markets, enabling them to become the absolute leader in a certain field, thereby capturing the largest market share and achieving the highest profit. Meanwhile, Boston Scientific...Is a leader in long-term medical devices, achieving comprehensive solutions by continuously doubling investment in key areas, thereby reaping high returns through synergistic effects.

Major Transactions of Johnson & Johnson and Boston Scientific in the Past Three Years

• Johnson & Johnson

• Abiomed ($16.6 billion): Interventional cardiac pump (Impella), targeting the $18 billion circulatory support market (CAGR 12%);
• Shockwave Medical ($13.1 billion): Shockwave Intravascular Lithotripsy (Shockwave IVL), $14 billion market for treating vascular calcification lesions with Shockwave IVL (Compound Annual Growth Rate of 23.6%);
• V-Wave ($1.7B): Atrial shunt technology for heart failure in a $7.0B market.
• Laminar ($400 million): This is Johnson & Johnson's only synergy-driven acquisition, forming a 1+1>2 effect with its Biosense Webster business, rivaling Boston Scientific's Watchman + FARAPULSE.

• Boco

• Relevant Medsystems ($850 million): Strengthening the pain management sector, entering the $25 billion spinal cord stimulation market for treating discogenic pain;
• Axonics ($37 billion): This is one of the few large-scale acquisitions by Boston Scientific, allowing it to enter the $17 billion market.Sacral Nerve ModulationMarket (CAGR 7%), Urology Product LineCollaborative；
• Silk Road Medical ($1.2 billion): Peripheral FieldCollaborative, TCAR technology is a unique treatment for carotid artery calcification in the $1.8 billion peripheral vascular market, capable of preventing strokes;
• Cortex: Electrophysiological coordination, Boston Scientific strengthens 3D mapping technology in the electrophysiology field, forming a highly synergistic effect with its PFA products;
• Bolt Medical ($660 million): Synergies in peripheral and coronary fields,对标Johnson & JohnsonShockwave Medical。